A new manuscript based on Pulmonary Hypertension Association Registry (PHAR) data examined ”Clinical Differences and Outcomes between Methamphetamine-Associated and Idiopathic Pulmonary Arterial Hypertension.”
The study by Nicholas Kolaitis, M.D., and colleagues recently was published in the Annals of the American Thoracic Society.
The study compared outcomes of methamphetamine-associated pulmonary arterial hypertension (PAH) and idiopathic PAH patients enrolled in PHAR, PHA’s patient registry. Findings showed that patients with meth-related PHA had less favorable hemodynamics, poorer PAH-specific health-related quality of life and were less likely to be offered advanced PAH-specific therapy.
The manuscript is based on the first multicenter study to characterize this disease state. It is one of three manuscripts based on PHAR data recently published or accepted for publication in peer-reviewed journals.
PHAR is an organized database that collects patient data to evaluate specific outcomes and helps researchers learn more about PH.
The manuscript’s publication is particularly timely. This week, PHA will address the link between methamphetamine use and PH in Facebook Live events in English and Spanish.
The English-language version of “Ask the Experts: “PH and Meth” features pulmonologist Ramona Doyle, M.D., at 3 p.m. EST Nov. 23.
The Spanish-language version is at 2 p.m. EST Nov. 24 with pulmonologists Vinicio de Jesus Perez, M.D., and Karla Cruz, M.D.
Learn more about both events, which can be viewed on Facebook or the PHA website.